EGF 受体( EGFR )是一典型的受体型 PTK ,它的主要信号通路是 Ras-MAPK 途径。A.正确B.错误
Ras-MAPK信号通路的Ras,是EGFR/Her2的下游,小G蛋白,结合GTP是其激活的状态2706 0 2022-03-29 08:47:30 未经作者授权,禁止转载 您当前的浏览器不支持 HTML5 播放器 请更换浏览器再试试哦~30 3 55 19 - 新学期一起学习 知识 科学科普 校园分享官 科学 细胞生物学 教师...
研究显示,EGFR介导的信号通路在多种消化道肿瘤的发生发展中起重要作用,以EGFR为靶点的治疗被认为是最有希望的结直肠癌治疗途径之一。本项目是在我们发现小肠腺癌中EGFR不突变而KRAS基因低突变的基础上,以EGFR介导的RAS/MAPK、PI3K信号通路为中心,通过体外细胞实验、移植瘤模型及人组织标本,采用EGFR配体阻断、靶向分子...
LIN-39 and the EGFR/RAS/MAPK pathway regulate C. elegans vulval morphogenesis via the VAB-23 zinc finger protein. Development. 2011; 138 (21):4649–60. doi: 10.1242/dev.071951. [ Cross Ref ]Pellegrino MW, Farooqui S, Fröhli E, Rehrauer H, Kaeser-Pebernard S, Müller F, . LIN...
In the present study we have investigated the mechanisms that eventually lead to resistance to the vertical suppression of MAPK pathway through combination of EGFR and MEK inhibition in a cellular model of primary resistance to anti-EGFR therapy constituted by KRAS mutated CRC cell lines....
#随记#RAS突变—— PI3K突变可以与RAS突变共存,但RAS突变通常与MAPK通路中EGFR和BRAF的突变相互排斥。这说明,RAS突变足够使MAPK而非PI3K通路失调。PI3K通路的激活通常是在化疗或MAPK通路抑制后,也就是对这两类治疗产生了抵抗。这提示MAPK和PI3K抑制的联合治疗在RAS突变的肿瘤中可能奏效。
Background:Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are standard treatment for advanced non-small cell lung cancer (NSCLC). However, the emergence of EGFR-TKIs resistance poses a big challenge to the treatment. Although several resistant mutations have been identified, ...
of the EGFR-RAS-RAF1-MAP2K-MAPK1/3 signaling pathway may play a critical role in w09-induced autophagy and apoptosis, but also imply that induction of autophagic cancer cell death through activation of the EGFR pathway may be a potential therapeutic strategy for EGFR-disregulated gastric tumors...
百度试题 题目. EGF 受体( EGFR )是一典型的受体型 PTK ,它的主要信号通路是 Ras-MAPK 途径。相关知识点: 试题来源: 解析 A 反馈 收藏
Identification of a negative regulator of the EGFR/RAS/MAPK pathway during vulval developmentStetak, AttilaStetak, AttilaHajnal, AlexHajnal, Alex